Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 open-label extension trial of elamipretide in patients with dry age-related macular degeneration (dry AMD)

Next Previous
Trial Profile

A phase 3 open-label extension trial of elamipretide in patients with dry age-related macular degeneration (dry AMD)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms ReTAIN

Most Recent Events

  • 16 Jun 2026 According to Stealth BioTherapeutics media release, Stealth BioTherapeutics is now called Mighty Therapeutics.
  • 18 Mar 2025 New trial record
  • 13 Mar 2025 According to a Stealth BioTherapeutics, In the ReNEW and ReGAIN trials, 360 patients will be randomized 2:1 to either elamipretide or placebo for 96 weeks with the option for participants to enroll in the open-label extension trial, ReTAIN.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top